9:20 am Chair’s Opening Remarks
Optimizing ADC Dosage to Minimize Toxicity, while Maximizing Efficacy & Improve Therapeutic Windows
9:30 am Incorporating Mitigation Strategies into Your Clinical Trial Design to Increase Your Dosage
Synopsis
- Discovering what you can do to manage toxicities in the clinic will allow for higher dosing for your ADC
- Hearing about most common toxicities and how these have been managed in previous case studies
- Discussing the severity of certain toxicities and the risks of relying on mitigation in the clinic
10:00 am Potential Mechanism of PBD Conjugate-Associated Fluid Retention in Patients
Synopsis
- Reviewing of AEs of effusions and edema in patients treated with various PBD conjugates
- Presenting toxicity findings in NHPs dosed with tool PBD compounds
- Hypothesizing the mechanism of fluid retention in patients
10:30 am The Utility of Clinical Biomarker Data for ADC Dose Selection
Synopsis
- Looking at how clinical biomarker data can be used to inform your dose selection and escalation
- Guiding dose response using an improved understanding of response
- Identifying clinical biomarkers for monitoring dose response
11:00 am Morning Refreshments & Networking
Advancing ADC Designs for Ideal Linker Stability & Antibody-Payload Ratio
11:30 am Identifying Conjugation Sites & Impacts of Bioconjugation Method/ DAR on FC Binding on ADC Toxicity Profiles
Synopsis
- Approaching your conjugation site identification
- Outlining the impacts of the bioconjugation method on Fc binding
- Discussing the implications of ADC design on tox profiles
12:00 pm Tumor Selective Linker Design to Optimize Therapeutic Index of ADCs
Synopsis
- Linker chemistry for effective conjugation and payload release
- Delving deeper into the linker-payload selection to balance safety and efficacy
- Matching linker-payload to targets to mitigate off- and on-target toxicities
12:30 pm Optimizing Linker Stability in ADC Design to Maximize Efficacy
Synopsis
- Finding the sweet spot between too reactive and not reactive enough
- Benefits of not having a linker that is too stable
- Testing for optimal linker stability to reduce off-target effects
1:00 pm Lunch & Networking
Discovering the Next-Generation of ADCs & Related Toxicities
2:00 pm Beyond Cell Killing Payloads: ADCs for Alternate Clinical Indications
Synopsis
- Looking into current research on non-cell killing payloads
- Identifying toxicological benefits of non-cell killing payloads
- Thinking about the future of novel ADCs
2:30 pm Building an ADC platform with Amanitin as a new payload and a novel mode of action
Synopsis
- Understanding the toxicity profile associated with the use of amatoxins as novel ADC payloads
- Optimizing the ADC technology towards Amanitin-based ADCs with a good therapeutic index
- Possibilities to optimize the therapeutic index of Amanitin-based ADCs by the route and schedule of administration
3:00 pm Panel: Learning from Previous ADC Development: What Can we Learn from Previous ADCs That Can Be Applied to Novel ADCs?
Synopsis
- Have we learned any lessons in the development of ADCs that we need to consider when developing novel ADCs?
- What are the toxicological considerations associated with developing novel ADCs?
- What are the preclinical and clinical challenges in developing novel ADCs?